Clinical Trial Update: Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery [NA]

View source ↗

Summary

A completed clinical trial comparing bromfenac 0.07% once daily to nepafenac 0.3% once daily for ocular inflammation after cataract surgery, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract
• Ocular Inflammation
• Retinal Edema

Drugs mentioned

• ILEVRO (nepafenac)
• Prolensa (bromfenac)

Snippet

Sponsor: Melissa Toyos | Conditions: Cataract, Retinal Edema | NA | Status: COMPLETED | Results posted: 2018-11-14